Atara Biotherapeutics (ATRA) vs OnKure Therapeutics (OKUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OnKure Therapeutics (OKUR) has outperformed Atara Biotherapeutics (ATRA) over the past year, losing 24.3% versus a loss of 41.8%. Over five years, OKUR leads with a -96.4% price change compared with -97.6% for ATRA. OnKure Therapeutics is the larger company by market cap ($93.1 million vs $92.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | OKUR |
|---|---|---|
| Share price | $9.23 | $2.30 |
| Market cap | $92.65M | $93.14M |
| 1-day change | -1.49% | -2.13% |
| YTD return | -48.98% | -20.69% |
| 1-year return | -41.77% | -24.34% |
| 5-year return | -97.56% | -96.43% |
| Forward P/E | 5.97 | — |
| EPS (TTM) | $-1.30 | $-3.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.15 | $5.38 |
| 52-week low | $3.92 | $2.13 |
| Distance from 52-week high | -51.79% | -57.25% |
| Analyst consensus | buy | none |
| Avg. price target upside | +48.10% | +573.91% |
| Average volume | 53.79K | 216.96K |
| Shares outstanding | 10.04M | 40.50M |
| Employees | 10 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKUR has outperformed ATRA by 17.4 percentage points over the past year.
About Atara Biotherapeutics
ATRA stock →Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
ATRA vs OKUR FAQ
Which is bigger, Atara Biotherapeutics or OnKure Therapeutics?
OnKure Therapeutics (OKUR) is larger, with a market capitalization of $93.14M compared with $92.65M for Atara Biotherapeutics (ATRA).
Which stock has performed better over the past year, ATRA or OKUR?
OKUR returned -24.34% over the past 12 months, compared with -41.77% for ATRA (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and OnKure Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Atara Biotherapeutics and Biotechnology: Pharmaceutical Preparations for OnKure Therapeutics.